Trial Profile
A randomized, double-bind, placebo-controlled, parallel-group, fixed-dose, multicenter study to assess efficacy and safety of rimonabant 20 mg versus placebo on weight loss and frequency of binge episodes in obese patients with food craving.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Apr 2013
Price :
$35
*
At a glance
- Drugs Rimonabant (Primary)
- Indications Eating disorders; Obesity
- Focus Therapeutic Use
- Sponsors Sanofi
- 14 Apr 2009 Actual end date (August 2005) added as reported by ClinicalTrials.gov.
- 31 Jul 2007 New trial record.